Hermes Investment Management Ltd. grew its holdings in Thermo Fisher Scientific Inc (NYSE:TMO) by 10.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 604,989 shares of the medical research company’s stock after purchasing an additional 55,912 shares during the quarter. Thermo Fisher Scientific comprises about 1.7% of Hermes Investment Management Ltd.’s portfolio, making the stock its 5th biggest position. Hermes Investment Management Ltd. owned approximately 0.16% of Thermo Fisher Scientific worth $114,464,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Mutual of America Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 2.2% in the 3rd quarter. Mutual of America Capital Management LLC now owns 48,772 shares of the medical research company’s stock valued at $9,228,000 after purchasing an additional 1,044 shares during the period. Shell Asset Management Co. lifted its stake in shares of Thermo Fisher Scientific by 164.7% in the 3rd quarter. Shell Asset Management Co. now owns 81,451 shares of the medical research company’s stock valued at $9,913,000 after purchasing an additional 50,684 shares during the period. Eqis Capital Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 5.6% in the 3rd quarter. Eqis Capital Management Inc. now owns 14,391 shares of the medical research company’s stock valued at $2,723,000 after purchasing an additional 768 shares during the period. Perigon Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific by 1.3% in the 2nd quarter. Perigon Wealth Management LLC now owns 31,251 shares of the medical research company’s stock valued at $5,457,000 after purchasing an additional 397 shares during the period. Finally, Intl Fcstone Inc. acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $276,000. 83.78% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.dailypolitical.com/2017/11/14/hermes-investment-management-ltd-has-114-46-million-stake-in-thermo-fisher-scientific-inc-tmo.html.

In other news, VP Peter E. Hornstra sold 3,894 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total value of $721,090.92. Following the completion of the transaction, the vice president now directly owns 19,751 shares of the company’s stock, valued at $3,657,490.18. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director C Martin Harris sold 360 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total value of $65,149.20. Following the completion of the transaction, the director now directly owns 5,312 shares of the company’s stock, valued at $961,312.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,738 shares of company stock valued at $4,021,512. 0.49% of the stock is currently owned by corporate insiders.

Shares of Thermo Fisher Scientific Inc (NYSE TMO) opened at $188.21 on Tuesday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. The company has a market capitalization of $74,657.32, a P/E ratio of 20.46, a price-to-earnings-growth ratio of 1.71 and a beta of 1.08. Thermo Fisher Scientific Inc has a twelve month low of $139.07 and a twelve month high of $201.20.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.24 by $0.07. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.03 EPS. sell-side analysts predict that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be issued a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.32%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.19%.

TMO has been the topic of a number of recent analyst reports. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $214.00 price objective on the stock in a research note on Thursday, September 14th. Bank of America Corporation reissued a “buy” rating and issued a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Cowen and Company reaffirmed a “buy” rating and set a $200.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, September 1st. Finally, Argus reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $205.71.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.